👀Tune in for @zunairkhm.bsky.social, unveilling the role of the gut microbiome in patient response to dietary interventions aimed at treating MacTel, a metabolic-associated hereditary vision-loss disorder. #MicroSeq2026 #microbiome #guthealth #visionloss
September 2, 2026 at 2:09 AM
👀Tune in for @zunairkhm.bsky.social, unveilling the role of the gut microbiome in patient response to dietary interventions aimed at treating MacTel, a metabolic-associated hereditary vision-loss disorder. #MicroSeq2026 #microbiome #guthealth #visionloss
A new study co-led by Prof. Martin Friedlander of Scripps Research, in collaboration with the NIH shows that ENCELTO—a now FDA-approved, cell-based retinal implant—can slow vision loss in MacTel, a rare degenerative eye disease.
Study confirms long-term benefit of implant for blinding eye disease
www.scripps.edu
August 11, 2025 at 6:06 PM
A new study co-led by Prof. Martin Friedlander of Scripps Research, in collaboration with the NIH shows that ENCELTO—a now FDA-approved, cell-based retinal implant—can slow vision loss in MacTel, a rare degenerative eye disease.
Hora do banho 🚿☺️🧼
#mactel #nsfw #gay #gaynudes #shorts #fetiche #boardshorts #hot #gayporn #hardcock #cock #homy #Exhibitionism #exibicionista #brasil #brazil #pelado
#sexy #piroca #pinto #tensão #pauduro
#PINTOAWARDS
#PINTOSAWARDS
#PINTOWARD
#PINTOAWARDSGAY
#BROTHERAGEM
#mactel #nsfw #gay #gaynudes #shorts #fetiche #boardshorts #hot #gayporn #hardcock #cock #homy #Exhibitionism #exibicionista #brasil #brazil #pelado
#sexy #piroca #pinto #tensão #pauduro
#PINTOAWARDS
#PINTOSAWARDS
#PINTOWARD
#PINTOAWARDSGAY
#BROTHERAGEM
October 26, 2024 at 6:39 AM
Macular telangiectasia type 2 (MacTel) gradually damages light-sensing cells in the retina, leading to vision loss. Scripps Research helped uncover its cause—and supported the first FDA-approved implant to treat it. 🧵
FDA approves ENCELTO, a first-of-its-kind eye implant that slows vision loss in rare eye disease
www.scripps.edu
October 10, 2025 at 7:20 PM
Macular telangiectasia type 2 (MacTel) gradually damages light-sensing cells in the retina, leading to vision loss. Scripps Research helped uncover its cause—and supported the first FDA-approved implant to treat it. 🧵
The @fda.gov has approved ENCELTO, a first-of-its-kind eye implant that slows vision loss in rare eye disease.
The cell-based therapy developed by Neurotech Pharmaceuticals with roots at Scripps Research offers new hope for patients with MacTel type 2.
The cell-based therapy developed by Neurotech Pharmaceuticals with roots at Scripps Research offers new hope for patients with MacTel type 2.
FDA approves ENCELTO, a first-of-its-kind eye implant that slows vision loss in rare eye disease
ow.ly
June 18, 2025 at 10:00 PM
The @fda.gov has approved ENCELTO, a first-of-its-kind eye implant that slows vision loss in rare eye disease.
The cell-based therapy developed by Neurotech Pharmaceuticals with roots at Scripps Research offers new hope for patients with MacTel type 2.
The cell-based therapy developed by Neurotech Pharmaceuticals with roots at Scripps Research offers new hope for patients with MacTel type 2.
ENCELTO is a small implant for macular telangiectasia (MacTel), a disease where abnormal blood vessels and retinal degeneration cause central vision loss
The implant uses modified retinal pigment epithelial cells to release ciliary neurotrophic factor (CNTF), to protect and preserve eye function
The implant uses modified retinal pigment epithelial cells to release ciliary neurotrophic factor (CNTF), to protect and preserve eye function
FDA Approves Encapsulated Cell Therapy for Degenerative Eye Disease
Encelto is the first and only approved treatment for MacTel type 2.
www.asgct.org
June 18, 2025 at 10:14 PM
ENCELTO is a small implant for macular telangiectasia (MacTel), a disease where abnormal blood vessels and retinal degeneration cause central vision loss
The implant uses modified retinal pigment epithelial cells to release ciliary neurotrophic factor (CNTF), to protect and preserve eye function
The implant uses modified retinal pigment epithelial cells to release ciliary neurotrophic factor (CNTF), to protect and preserve eye function
John B. Miller et al. investigate retinal microvascular and choriocapillaris changes across the newly proposed seven-step classification for macular telangiectasia type 2 (MacTel) using swept-source optical coherence tomography angiography.
doi.org/10.1167/iovs.67.2.44
doi.org/10.1167/iovs.67.2.44
February 23, 2026 at 7:13 PM
John B. Miller et al. investigate retinal microvascular and choriocapillaris changes across the newly proposed seven-step classification for macular telangiectasia type 2 (MacTel) using swept-source optical coherence tomography angiography.
doi.org/10.1167/iovs.67.2.44
doi.org/10.1167/iovs.67.2.44
Ophthopedia Update: VIDEO: Three trials reinforce positive results of MacTel treatment: KOLOA, Hawaii — In this Healio Video Perspective from Retina 2025, W. Lloyd Clark, MD, discusses positive results from three clinical trials investigating NT-501 for macular telangiectasia type 2.
Compared with…
Compared with…
VIDEO: Three trials reinforce positive results of MacTel treatment
KOLOA, Hawaii — In this Healio Video Perspective from Retina 2025, W. Lloyd Clark, MD, discusses positive results from three clinical trials investigating NT-501 for macular telangiectasia type 2.
Compared with sham, patients implanted with NT-501…
dlvr.it
February 7, 2025 at 5:32 PM
Ophthopedia Update: VIDEO: Three trials reinforce positive results of MacTel treatment: KOLOA, Hawaii — In this Healio Video Perspective from Retina 2025, W. Lloyd Clark, MD, discusses positive results from three clinical trials investigating NT-501 for macular telangiectasia type 2.
Compared with…
Compared with…
An optical coherence tomography (OCT) scan shows the damage beneath the retinal surface in MacTel, where cystic spaces form and disrupt how the eye processes light. The disease progresses slowly, often without symptoms, but eventually impacts reading, facial recognition, and daily tasks.
October 10, 2025 at 7:20 PM
An optical coherence tomography (OCT) scan shows the damage beneath the retinal surface in MacTel, where cystic spaces form and disrupt how the eye processes light. The disease progresses slowly, often without symptoms, but eventually impacts reading, facial recognition, and daily tasks.
The U.S. FDA has recently approved the following:
- Encelto for the treatment of MacTel
- Amvuttra for the treatment of ATTR-CM
- Fabhalta for the treatment of C3G
- Vykat XR for the treatment of hyperphagia in PWS
Learn more at checkrare.com/2025-orphan-...
#CheckRare #FDAApproval #RareDisease
- Encelto for the treatment of MacTel
- Amvuttra for the treatment of ATTR-CM
- Fabhalta for the treatment of C3G
- Vykat XR for the treatment of hyperphagia in PWS
Learn more at checkrare.com/2025-orphan-...
#CheckRare #FDAApproval #RareDisease
March 31, 2025 at 5:13 PM
The U.S. FDA has recently approved the following:
- Encelto for the treatment of MacTel
- Amvuttra for the treatment of ATTR-CM
- Fabhalta for the treatment of C3G
- Vykat XR for the treatment of hyperphagia in PWS
Learn more at checkrare.com/2025-orphan-...
#CheckRare #FDAApproval #RareDisease
- Encelto for the treatment of MacTel
- Amvuttra for the treatment of ATTR-CM
- Fabhalta for the treatment of C3G
- Vykat XR for the treatment of hyperphagia in PWS
Learn more at checkrare.com/2025-orphan-...
#CheckRare #FDAApproval #RareDisease
Adee Tulcan is spending her summer in a lab researching MacTel, a degenerative eye disease that affects central vision. But her story goes beyond experiments and microscopes. It’s about faith, mentorship, storytelling, and a growing dream of becoming a physician-scientist.
https://bit.ly/4yAt8T7
https://bit.ly/4yAt8T7
Where Science Meets Faith: Adee Tulcan’s PLNU Journey | Viewpoint
Adee Tulcan came to PLNU with dreams of pursuing medical school and her biology education is helping those dreams take shape.
viewpoint.pointloma.edu
August 5, 2026 at 6:58 PM
Adee Tulcan is spending her summer in a lab researching MacTel, a degenerative eye disease that affects central vision. But her story goes beyond experiments and microscopes. It’s about faith, mentorship, storytelling, and a growing dream of becoming a physician-scientist.
https://bit.ly/4yAt8T7
https://bit.ly/4yAt8T7
A surgically implanted device that delivers a neuroprotective protein has been shown to slow vision loss in people with macular telangiectasia type 2 over a 24-month period. doi.org/g9wjrb
Study confirms long-term benefit of implant for blinding eye disease
For people with macular telangiectasia type 2 (MacTel), an orphan retinal disorder that gradually destroys central vision, there have long been no approved treatment options.
medicalxpress.com
August 8, 2025 at 1:41 PM
A surgically implanted device that delivers a neuroprotective protein has been shown to slow vision loss in people with macular telangiectasia type 2 over a 24-month period. doi.org/g9wjrb
The FDA has approved the first implantable device to slow vision loss in macular telangiectasia type 2, delivering a neuroprotective protein directly to the retina over the long term.
FDA approves a first-of-its-kind eye implant that slows vision loss in rare eye disease
For people diagnosed with macular telangiectasia type 2 (MacTel)—a rare and slowly progressing retinal disease—there have been no FDA-approved (or other) treatments to slow or stop vision loss.
medicalxpress.com
June 5, 2025 at 3:32 AM
The FDA has approved the first implantable device to slow vision loss in macular telangiectasia type 2, delivering a neuroprotective protein directly to the retina over the long term.
20 for me. Started in computers with the sinclairs used dialup modem to access MacTel based out of Nottingham. 300 baud to start then 1200 and eventually a 9600 one. Everything else is just what you did. Paul Burnett on radio charts on a Sunday, trying to stop recording when he spoke.
September 27, 2026 at 7:28 AM
20 for me. Started in computers with the sinclairs used dialup modem to access MacTel based out of Nottingham. 300 baud to start then 1200 and eventually a 9600 one. Everything else is just what you did. Paul Burnett on radio charts on a Sunday, trying to stop recording when he spoke.
Meet Rich Small, the CPA who turned a Rhode Island biotech into the maker of the first FDA-approved MacTel treatment.
Full story on https://yespress.io/rich-small?utm_source=bluesky&utm_medium=social
Full story on https://yespress.io/rich-small?utm_source=bluesky&utm_medium=social
Rich Small - The CPA Who Shipped an Eye Drug
How a Northeastern-trained accountant ended up leading one of ophthalmology
yespress.io
August 11, 2026 at 2:16 AM
Meet Rich Small, the CPA who turned a Rhode Island biotech into the maker of the first FDA-approved MacTel treatment.
Full story on https://yespress.io/rich-small?utm_source=bluesky&utm_medium=social
Full story on https://yespress.io/rich-small?utm_source=bluesky&utm_medium=social
Ophthopedia Update: Pooled Analyses of Anatomic and Visual Function Data of Revakinagene Taroretcel-lwey in Participants with Macular Telangiectasia Type 2: To assess anatomic and visual function data from 3 randomized, sham-controlled clinical trials of… #Ophthalmology #Retina #Ophthotwitter
Pooled Analyses of Anatomic and Visual Function Data of Revakinagene Taroretcel-lwey in Participants with Macular Telangiectasia Type 2
To assess anatomic and visual function data from 3 randomized, sham-controlled clinical trials of revakinagene taroretcel-lwey in participants with macular telangiectasia type 2 (MacTel).
dlvr.it
July 20, 2026 at 12:19 PM
Ophthopedia Update: Pooled Analyses of Anatomic and Visual Function Data of Revakinagene Taroretcel-lwey in Participants with Macular Telangiectasia Type 2: To assess anatomic and visual function data from 3 randomized, sham-controlled clinical trials of… #Ophthalmology #Retina #Ophthotwitter